Floatz logo

MIDAZOLAM

Alcohol Use Disorder

VA Office of Research and DevelopmentSmall moleculePhase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Alcohol Use Disorder cohort.

Asset / SponsorPhaseRating
Naltrexone
VA Connecticut Healthcare System
Phase 4BBB
17.BETA.-(1-KETOETHYL)-.DELTA. SUP(5)-ANDROSTEN-3.BETA.-OL
Sherwood Brown, MD, PhD
Phase 4BB
Zofran
University of Texas Southwestern Medical Center
Phase 4BB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Centre hospitalier de l'Université de Montréal (CHUM)
Phase 2BB
MIRTAZAPINE
University of Pittsburgh
Phase 2B

View all 19 →

Same molecule, other indications

MIDAZOLAM is also rated in:

gastrointestinal stromal tumorDormant
BBB
Indicative ·
75 / 100
View asset →
neuralgiaDormant
BBB
Indicative ·
75 / 100
View asset →
epilepsyDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →